Samsung Biologics raised its revenue forecast for the year to $2.65 billion, citing new contract manufacturing deals and increased production capabilities.
SK bioscience will acquire a 6.5 percent stake, or 6.5 million shares, in Novavax, a U.S. vaccine developer.
Samsung Biologics will start partial operation of its fourth plant in Songdo, Incheon, in October this year, with plans to break ground on a fifth factory in the first half.
Korea JoongAng Daily Sitemap